Table 3. Late Adverse Events IMRT versus 3DCRT NRG Oncology RTOG 0539 versus NRG Oncology RTOG 0424.
Trial | n | Grade 2+ | Grade 2 | Grade 3 | Grade 4 |
---|---|---|---|---|---|
RTOG 0539 (IMRT) | 43 | 25.6% | 25.6% | 0 | 0 |
RTOG 0424 (3DCRT) | 52 | 43% | 33% | 8% | 2% |
Trial | n | Grade 2+ | Grade 2 | Grade 3 | Grade 4 |
---|---|---|---|---|---|
RTOG 0539 (IMRT) | 43 | 25.6% | 25.6% | 0 | 0 |
RTOG 0424 (3DCRT) | 52 | 43% | 33% | 8% | 2% |